LGALS3 and atherosclerosis: Based on the results of this study it can be concluded that even in the group with stable coronary disease, there is still a group of patients who will have a worse clinical outcome despite revascularization and optimal medical therapy, it is evident that the pathophysiological process of atherosclerosis and destabilization persists in such patients, and to prevent MACE events, it is necessary to reduce the activity of macrophages, and the secretion of Gal-3.